07.04.26 -- Maintaining Compliance And Understanding FDA Expectations

Happy 250th birthday, USA! In honor of the holiday, this weekend’s editorial focus is patriotically centered on the FDA — specifically, around inspectional readiness, compliance, and responding to Form 483 observations.

This guest column from ELIQUENT Life Sciences’ David Elder outlines the FDA’s use of AI tools during inspection activities and provides guidance to help companies prepare for these AI-supported inspections.

In the unfortunate event that an inspection surfaces issues relating to product quality, safety, or noncompliance, a response is required. This column by Peter Calcott, Ph.D., FRSC, president and CEO of Calcott Consulting, summarizes the FDA’s expectations for responses to Form 483 observations.

Of course, being proactive — i.e., running a tight ship and maintaining compliance — is always better than being reactive. Check out this guest column on the most common and consequential compliance gaps in sterile manufacturing by Pharmatech Associates’ president and CSO, Bikash Chatterjee.

Before you go, be sure to check out some selected content from our partners below!

Tyler Menichiello                              
Chief Editor, Bioprocess Online

West Pharmaceutical Services explores why proactive, risk-based contamination control is becoming a global expectation—helping manufacturers strengthen compliance.

Emulate shares how human-relevant testing strategies are reshaping drug development, as regulators push more predictive paths for safety and efficacy.

ACROBiosystems clarifies the standards and supply chain safeguards behind compliant CGT materials—see how stronger quality systems can support manufacturing readiness.

Minaris provides practical strategies for viral clearance studies that meet evolving global expectations, helping teams strengthen submissions and move forward with confidence.

Lonza helps drug developers gain critical months before IND by accelerating tox material readiness and easing a growing bottleneck.

CAI explains why the FDA’s shift to agentic AI will reshape regulatory reviews, exposing weak processes and rewarding organizations built for data integrity.

InQuest Science shows why digital defect libraries are now essential for consistent visual inspection and safer sterile manufacturing—learn what modern compliance demands.